The U.S. Centers for Disease Control and Prevention (CDC) has revised its guidance on COVID-19 vaccines for children, stating that vaccination for healthy individuals aged 6 months to 17 years should follow a “shared clinical decision-making” process. This means that shots are still available, but only if parents and doctors agree it's necessary based on individual circumstances.
The move marks a shift from earlier CDC guidance, which broadly recommended updated COVID-19 vaccines for everyone six months and older. The updated schedule, published Thursday, outlines that if parents want their child vaccinated, they may proceed based on a healthcare provider’s judgment and the family’s preference.
Health Secretary Robert F. Kennedy Jr., a known vaccine skeptic, claimed earlier in the week that COVID vaccines for healthy children and pregnant women had been removed from the CDC’s immunization schedule. However, a Department of Health and Human Services spokesperson said there is no contradiction, as the CDC’s updated guidance no longer promotes universal vaccination for healthy children but still allows it case-by-case.
Medical experts criticized Kennedy’s unilateral announcement, saying it bypassed the CDC’s usual advisory process. The Infectious Diseases Society of America warned the change may limit access and insurance coverage, especially for vulnerable children. They emphasized that COVID-19 can cause serious illness in children, including long COVID symptoms that may impact development.
According to CDC data, nearly 1,900 children under 18 have died from COVID-19 in the U.S. as of 2023. Vaccine makers Pfizer, Moderna, and Novavax have not commented on the development.
The FDA also recently announced it would require new clinical trials for annual COVID boosters in healthy individuals under 65, reinforcing a more limited use strategy moving forward.


SEC Investor Reform Validates Barry Silbert’s Tokenization Vision
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
FDA Weighs Safety Standards for Psychedelic Therapies
US Waives $320M Egypt Military Aid Conditions After Iran War Role
EU Gives Crypto Platforms Three Months to Remove USDT Under MiCA Rules
Saudi Arabia Probes Flydubai Cockpit Attack
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal
OpenAI, Anthropic Back Mandatory AI Breach Reporting in Australia
Circle Urges EU to Revise MiCA Stablecoin Rules
US Conducts Non-Nuclear Explosion Test to Boost Nuclear Detection
Illinois Delays Crypto Tax Law Until July 2027
New York Declares Measles Disaster Emergency as Cases Surge
Trump Weighs FBI Probe Into Nolan Wells’ Death
HUTCHMED, AstraZeneca Seek FDA Approval for Lung Cancer Combo 



